Quantitative RARbeta2 hypermethylation: a promising prostate cancer marker

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Carmen JerónimoDavid Sidransky

Abstract

Retinoic acid receptor beta2 (RARbeta2) is a tumor suppressor gene frequently hypermethylated in several human neoplasms. To further characterize this epigenetic alteration in prostate cancer progression, we examined tumor tissue from 118 patients with prostate carcinoma (PCa), 38 paired high-grade prostatic intraepithelial neoplasias (HGPIN), and non-neoplastic prostate tissue from 30 patients with benign prostate hyperplasia (BPH), using quantitative methylation-specific PCR. We found RARbeta2 hypermethylation in 97.5% of PCa, 94.7% of HGPIN, and 23.3% of BPH. Methylation levels were significantly higher in PCa compared with HGPIN and BPH (P < 0.00001). By establishing an empiric cutoff value, we were able to discriminate between neoplastic and non-neoplastic tissue, with 94.9% sensitivity and 100% specificity. Moreover, RARbeta2 methylation levels correlated with higher pathological stage (r = 0.30, P = 0.0009). This quantitative assay represents a novel and promising molecular marker that may augment current approaches for prostate cancer detection.

References

Mar 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·M FrommerC L Paul
Jun 1, 1993·Human Pathology·M H Weinstein, J I Epstein
Feb 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·B HouleW E Bradley
Jul 1, 1996·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·R Lotan
Oct 28, 1998·Journal of the National Cancer Institute·C M MoinpourF L Meyskens
Mar 2, 1999·Journal of the National Cancer Institute·S A AhrendtD Sidransky
Jan 7, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y LotanD Kadmon
Mar 29, 2000·CA: a Cancer Journal for Clinicians·R T GreenleeP A Wingo
May 18, 2000·Journal of the National Cancer Institute·M WidschwendterC Marth
Aug 17, 2000·Journal of the National Cancer Institute·A K VirmaniA F Gazdar
Nov 22, 2001·Journal of the National Cancer Institute·C JerónimoD Sidransky
Mar 22, 2003·Lancet·Angelo M DeMarzoJonathan I Epstein
Jul 8, 2003·International Journal of Cancer. Journal International Du Cancer·Mikio YamanakaTaizo Shiraishi
Nov 6, 2003·Journal of the National Cancer Institute·Susan V HardenDavid Sidransky

❮ Previous
Next ❯

Citations

Nov 30, 2006·Journal of Applied Genetics·Jaroslaw Paluszczak, Wanda Baer-Dubowska
Oct 4, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Rui HenriqueCarmen Jerónimo
Jul 27, 2007·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·I Ibáñez de Cáceres, P Cairns
Dec 27, 2011·Cancer Letters·Carmen Jerónimo, Rui Henrique
Apr 7, 2005·DNA and Cell Biology·Rui HenriqueDavid Sidransky
Jun 25, 2005·Journal of Clinical Pathology·C HughesJ O'Leary
Oct 29, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Mariana BraitMohammad Obaidul Hoque
Jun 4, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Juan-Miguel MosqueraMark A Rubin
Dec 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Takuji MoriDave S B Hoon
Jun 13, 2009·Endocrinology·William G NelsonSrinivasan Yegnasubramanian
May 6, 2014·Critical Reviews in Oncology/hematology·Molin LiChuangang Li
Nov 16, 2010·Annual Review of Pathology·Xiao-Han Tang, Lorraine J Gudas
Jul 31, 2010·Obstetrics and Gynecology International·Krishna Vanaja DonkenaDonald J Tindall
Jun 7, 2005·Expert Opinion on Therapeutic Targets·Judith R FayLevy Kopelovich
Apr 22, 2009·Expert Review of Molecular Diagnostics·Mohammad Obaidul Hoque
Jul 2, 2011·European Urology·Carmen JerónimoShahrokh F Shariat
Jul 21, 2005·British Journal of Haematology·Kai BrakensiekUlrich Lehmann
Jan 4, 2012·Histopathology·Glen Kristiansen
Dec 23, 2011·Prostate Cancer·Costantine AlbanyNoah M Hahn
Mar 8, 2006·Urologic Oncology·Zhengwang ZhangJer-Tsong Hsieh
Jul 20, 2007·Differentiation; Research in Biological Diversity·Nigel P Mongan, Lorraine J Gudas
Jul 24, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Danjie JiangShiwei Duan
Oct 9, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Sara Monteiro-ReisCarmen Jerónimo
Apr 21, 2011·Cancer Genetics·Guangyu Gu, Arthur R Brothman
Jan 17, 2015·Annales d'endocrinologie·Mawussi AdjaklyDominique Bernard-Gallon
Oct 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice BarlésiJose Antonio Rodriguez
Sep 20, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mohammad Obaidul HoqueDavid Sidransky
May 26, 2015·Current Pharmacology Reports·Neelam MukherjeeRita Ghosh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Carmen JerónimoDavid Sidransky
International Journal of Cancer. Journal International Du Cancer
Mikio YamanakaTaizo Shiraishi
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Hideki EnokidaRajvir Dahiya
© 2022 Meta ULC. All rights reserved